The Short-Term Placebo Response in Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Area of Science:

• Pediatric Psychology
• Neurodevelopmental Disorders
• Clinical Psychology

Background:

• Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder in children.
• Understanding placebo response is crucial for accurate ADHD treatment assessment.
• Short-term placebo effects can influence treatment outcomes in pediatric populations.

Purpose of the Study:

• To evaluate the prevalence and characteristics of short-term placebo response in children diagnosed with ADHD.
• To investigate the relationship between placebo response and methylphenidate response in this population.
• To identify factors associated with placebo response in pediatric ADHD.

Main Methods:

• A double-blind, placebo-controlled trial was conducted with children aged 6-13 years with ADHD.
• Participants received placebo and methylphenidate for one week each.
• Standardized assessments included Conners' Rating Scales, the Aggregate Neurobehavioral Student Health and Educational Review, and the Matching Familiar Figure Test.

Main Results:

• Approximately 18.8% of children showed a significant reduction in teacher-reported ADHD symptoms on placebo.
• Attention test performance improved in 58% (reduced errors) and 36.2% (increased latency) under placebo.
• Placebo response significantly correlated with methylphenidate response across teacher rating subscales.
• Baseline symptom severity, learning problems, and emotional status were associated with placebo response.

Conclusions:

• Short-term placebo response is a notable phenomenon in children with ADHD.
• Clinicians should consider placebo effects when interpreting treatment outcomes in pediatric ADHD.
• The findings highlight the importance of placebo-controlled trials for robust ADHD treatment evaluation.